Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Phase IV Multicentric Study, 140 Patients Suffering of Meibomian Glands Dysfunction.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01189474

Acronym

ESPOIR Ext

Enrollment

104

Registered

2010-08-26

Start date

2010-06-30

Completion date

2011-12-31

Last updated

2012-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eyelid Diseases

Keywords

Meibomian Gland Dysfunction

Brief summary

Multicentric study, open label, uncontrolled phase IV in 140 patients with meibomian glands dysfunction . Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized. This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21. Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.

Interventions

DEVICEBlephasteam

Eye lid warming goggles

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

4 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed and dated informed consent. * Male or female up to 4 years old. * Known and treated symptomatic Meibomian Gland Diseases, and/or Dry Eye related to MGDs stable since at least a month. * Without any active pathology requiring a change in ocular treatments within the last month before inclusion. * Best corrected far visual acuity (VA) \> 1/10

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026